HANNA CUNNINGHAM: Open Payments
NPI 1689179251 · MANCHESTER, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$521 in 29 payments from 14 companies in 2025. Trend: 2023 $603 · 2024 $451 · 2025 $521
Food & beverage: $521
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 5 | $96 |
| Phathom Pharmaceuticals, Inc. | 4 | $62 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $56 |
| Novo Nordisk Inc | 3 | $55 |
| AstraZeneca Pharmaceuticals LP | 3 | $51 |
| ABBVIE INC. | 2 | $43 |
| Lilly USA, LLC | 2 | $38 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $19 |
Products named: TRELEGY ELLIPTA, VOQUEZNA, CAPLYTA, Ozempic, RECORLEV, VRAYLAR, UBRELVY, Kerendia.
Industry payments across TN — which companies pay providers there.
